Initial Uptake, Time to Treatment, and Real-world Effectiveness of All-oral Direct-acting Antivirals for Hepatitis C Virus Infection in the United States: A Retrospective Cohort Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Aug 23

PMID 31437170

Citations 8

Authors

Paul Y Kwo

Amy Puenpatom

Zuoyi Zhang

Siu L Hui

Andrea A Kelley

David Muschi

Affiliations

Soon will be listed here.

Abstract

Background: Data on initiation and utilization of direct-acting antiviral therapies for hepatitis C virus infection in the United States are limited. This study evaluated treatment initiation, time to treatment, and real-world effectiveness of direct-acting antiviral therapy in individuals with hepatitis C virus infection treated during the first 2 years of availability of all-oral direct-acting antiviral therapies.

Methods: A retrospective cohort analysis was undertaken using electronic medical records and chart review abstraction of hepatitis C virus-infected individuals aged >18 years diagnosed with chronic hepatitis C virus infection between January 1, 2014, and December 31, 2015 from the Indiana University Health database.

Results: Eight hundred thirty people initiated direct-acting antiviral therapy during the 2-year observation window. The estimated incidence of treatment initiation was 8.8%±0.34% at the end of year 1 and 15.0%±0.5% at the end of year 2. Median time to initiating therapy was 300 days. Using a Cox regression analysis, positive predictors of treatment initiation included age (hazard ratio, 1.008), prior hepatitis C virus treatment (1.74), cirrhosis (2.64), and history of liver transplant (1.5). History of drug abuse (0.43), high baseline alanine aminotransferase levels (0.79), hepatitis B virus infection (0.41), and self-pay (0.39) were negatively associated with treatment initiation. In the evaluable population (n = 423), 83.9% (95% confidence interval, 80.1-87.3%) of people achieved sustained virologic response.

Conclusion: In the early years of the direct-acting antiviral era, <10% of people diagnosed with chronic hepatitis C virus infection received direct-acting antiviral treatment; median time to treatment initiation was 300 days. Future analyses should evaluate time to treatment initiation among those with less advanced fibrosis.

Citing Articles

Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study.

Rennert L, Howard K, Kickham C, Gezer F, Coleman A, Roth P Lancet Reg Health Am. 2023; 29:100648.

PMID: 38124995 PMC: 10733089. DOI: 10.1016/j.lana.2023.100648.

Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C.

Parums D Med Sci Monit. 2023; 29:e940519.

PMID: 37002682 PMC: 10075002. DOI: 10.12659/MSM.940519.

Rapid Treatment Initiation for Hepatitis C Virus Infection: Potential Benefits, Current Limitations, and Real-World Examples.

Finbraten A, Eckhardt B, Kapadia S, Marks K Gastroenterol Hepatol (N Y). 2023; 18(11):628-638.

PMID: 36866028 PMC: 9972665.

Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.

Wang A, Hsieh E, Turner B, Terrault N J Gen Intern Med. 2022; 37(13):3435-3443.

PMID: 35484367 PMC: 9551010. DOI: 10.1007/s11606-022-07628-9.

Using Health Information Technology to Create Pathways for Hepatitis C Treatment and Cure in West Virginia.

Baus A, Calkins A, Feinberg J, McManaway K, Moser S, Pollard C Perspect Health Inf Manag. 2022; 19(1):1j.

PMID: 35440923 PMC: 9013224.

References

McHutchison J, Lawitz E, Shiffman M, Muir A, Galler G, McCone J . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6):580-93. DOI: 10.1056/NEJMoa0808010. View

Davis G, Alter M, El-Serag H, Poynard T, Jennings L . Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2009; 138(2):513-21, 521.e1-6. DOI: 10.1053/j.gastro.2009.09.067. View

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

North C, Hong B, Adewuyi S, Pollio D, Jain M, Devereaux R . Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2012; 35(2):122-8. DOI: 10.1016/j.genhosppsych.2012.11.002. View

Jacobson I, Gordon S, Kowdley K, Yoshida E, Rodriguez-Torres M, Sulkowski M . Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20):1867-77. DOI: 10.1056/NEJMoa1214854. View

Holmberg S, Spradling P, Moorman A, Denniston M . Hepatitis C in the United States. N Engl J Med. 2013; 368(20):1859-61. PMC: 5672915. DOI: 10.1056/NEJMp1302973. View

Vaidya A, Perry C . Simeprevir: first global approval. Drugs. 2013; 73(18):2093-106. DOI: 10.1007/s40265-013-0153-9. View

Kowdley K, Gordon S, Reddy K, Rossaro L, Bernstein D, Lawitz E . Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370(20):1879-88. DOI: 10.1056/NEJMoa1402355. View

10.

Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D . Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1594-603. DOI: 10.1056/NEJMoa1315722. View

11.

Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K . ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21):1973-82. DOI: 10.1056/NEJMoa1402869. View

12.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M . Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370(20):1889-98. DOI: 10.1056/NEJMoa1402454. View

13.

Gordon S, Muir A, Lim J, Pearlman B, Argo C, Ramani A . Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2014; 62(2):286-93. PMC: 4586075. DOI: 10.1016/j.jhep.2014.08.052. View

14.

Zeuzem S, Ghalib R, Reddy K, Pockros P, Ben Ari Z, Zhao Y . Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015; 163(1):1-13. DOI: 10.7326/M15-0785. View

15.

. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3):932-54. DOI: 10.1002/hep.27950. View

16.

Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C . Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLoS One. 2015; 10(8):e0135645. PMC: 4552165. DOI: 10.1371/journal.pone.0135645. View

17.

Sulkowski M, Vargas H, Di Bisceglie A, Kuo A, Reddy K, Lim J . Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2015; 150(2):419-29. PMC: 4727992. DOI: 10.1053/j.gastro.2015.10.013. View

18.

Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S . Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016; 64(2):370-80. PMC: 5412860. DOI: 10.1002/hep.28467. View

19.

Backus L, Belperio P, Shahoumian T, Loomis T, Mole L . Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016; 64(2):405-14. DOI: 10.1002/hep.28625. View

20.

Ho S, Monto A, Peyton A, Kaplan D, Byrne S, Moon S . Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clin Gastroenterol Hepatol. 2016; 15(2):282-288. DOI: 10.1016/j.cgh.2016.05.024. View